A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response

Summary Combining peginterferon (PEG‐IFN) and a potent nucleoside/nucleotide analogue might improve treatment response in patients with chronic hepatitis B (CHB). The aims of this study were to compare the efficacy of PEG‐IFN alpha‐2b with or without entecavir in HBeAg‐negative CHB and to investigat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of viral hepatitis 2016-06, Vol.23 (6), p.427-438
Hauptverfasser:	Tangkijvanich, P., Chittmittraprap, S., Poovorawan, K., Limothai, U., Khlaiphuengsin, A., Chuaypen, N., Wisedopas, N., Poovorawan, Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antiviral Agents - administration & dosage DNA, Viral - blood entecavir Female Guanine - administration & dosage Guanine - analogs & derivatives HBsAg quantification Hepatitis B e Antigens - blood Hepatitis B Surface Antigens - blood Hepatitis B, Chronic - drug therapy Humans Interferon-alpha - administration & dosage Male Middle Aged peginterferon Polyethylene Glycols - administration & dosage polymorphisms Prospective Studies Recombinant Proteins - administration & dosage stopping rule Treatment Outcome Viral Load Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!